CytoMed Therapeutics (NASDAQ:GDTC) Stock Rating Reaffirmed by Benchmark
Benchmark reaffirmed their speculative buy rating on shares of CytoMed Therapeutics (NASDAQ:GDTC – Free Report) in a report issued on Monday morning, Benzinga reports. Benchmark currently has a $5.00 price objective on the stock. CytoMed Therapeutics Trading Down 0.7 % Shares of GDTC opened at $3.45 on Monday. The stock has a 50 day moving […]
More Stories
ARS Wealth Advisors Group LLC Buys 6,223 Shares of Schwab US Broad Market ETF (NYSEARCA:SCHB)
ARS Wealth Advisors Group LLC increased its stake in shares of Schwab US Broad Market ETF (NYSEARCA:SCHB – Free Report)...
Stonebridge Capital Management Inc. Sells 250 Shares of Target Co. (NYSE:TGT)
Stonebridge Capital Management Inc. cut its stake in Target Co. (NYSE:TGT – Free Report) by 11.1% in the fourth quarter,...
Sendero Wealth Management LLC Buys 172 Shares of Mastercard Incorporated (NYSE:MA)
Sendero Wealth Management LLC boosted its position in Mastercard Incorporated (NYSE:MA – Free Report) by 3.8% in the 4th quarter,...
Apella Capital LLC Has $4.95 Million Stake in Vanguard S&P 500 ETF (NYSEARCA:VOO)
Apella Capital LLC increased its holdings in Vanguard S&P 500 ETF (NYSEARCA:VOO – Free Report) by 1.3% in the fourth...
Vanguard FTSE Emerging Markets ETF (NYSEARCA:VWO) Shares Sold by MPS Loria Financial Planners LLC
MPS Loria Financial Planners LLC trimmed its stake in shares of Vanguard FTSE Emerging Markets ETF (NYSEARCA:VWO – Free Report)...
GE Vernova (NYSE:GEV) Trading Up 1.8% Following Analyst Upgrade
GE Vernova Inc. (NYSE:GEV – Get Free Report) shares traded up 1.8% during trading on Thursday after Truist Financial raised...